572 related articles for article (PubMed ID: 26285815)
21. Functional significance of the novel H-RAS gene mutation M72I in a patient with medullary thyroid cancer.
Barollo S; Pezzani R; Cristiani A; Bertazza L; Rubin B; Bulfone A; Pelizzo MR; Torresan F; Mantero F; Pennelli G; Moro S; Mian C
Exp Clin Endocrinol Diabetes; 2013 Oct; 121(9):546-50. PubMed ID: 23934677
[TBL] [Abstract][Full Text] [Related]
22. Germline and somatic mutations in an oncogene: RET mutations in inherited medullary thyroid carcinoma.
Marsh DJ; Andrew SD; Eng C; Learoyd DL; Capes AG; Pojer R; Richardson AL; Houghton C; Mulligan LM; Ponder BA; Robinson BG
Cancer Res; 1996 Mar; 56(6):1241-3. PubMed ID: 8640806
[TBL] [Abstract][Full Text] [Related]
23. A case of advanced medullary thyroid carcinoma successfully treated with sunitinib.
Bugalho MJ; Domingues R; Borges A
Oncologist; 2009 Nov; 14(11):1083-7. PubMed ID: 19887470
[TBL] [Abstract][Full Text] [Related]
24. Diversity of mutations in the RET proto-oncogene and its oncogenic mechanism in medullary thyroid cancer.
Hedayati M; Zarif Yeganeh M; Sheikholeslami S; Afsari F
Crit Rev Clin Lab Sci; 2016 Aug; 53(4):217-27. PubMed ID: 26678667
[TBL] [Abstract][Full Text] [Related]
25. Medullary Thyroid Cancer - Feature Review and Update on Systemic Treatment.
Dabelić N; Jukić T; Fröbe A
Acta Clin Croat; 2020 Jun; 59(Suppl 1):50-59. PubMed ID: 34219884
[TBL] [Abstract][Full Text] [Related]
26. RET genetic screening in patients with medullary thyroid cancer and their relatives: experience with 807 individuals at one center.
Elisei R; Romei C; Cosci B; Agate L; Bottici V; Molinaro E; Sculli M; Miccoli P; Basolo F; Grasso L; Pacini F; Pinchera A
J Clin Endocrinol Metab; 2007 Dec; 92(12):4725-9. PubMed ID: 17895320
[TBL] [Abstract][Full Text] [Related]
27. Somatic mutations in the RET proto-oncogene in sporadic medullary thyroid carcinomas.
Dvorakova S; Vaclavikova E; Sykorova V; Vcelak J; Novak Z; Duskova J; Ryska A; Laco J; Cap J; Kodetova D; Kodet R; Krskova L; Vlcek P; Astl J; Vesely D; Bendlova B
Mol Cell Endocrinol; 2008 Mar; 284(1-2):21-7. PubMed ID: 18282654
[TBL] [Abstract][Full Text] [Related]
28. Medullary thyroid carcinoma: pitfalls in diagnosis by fine needle aspiration cytology and relationship of cytomorphology to RET proto-oncogene mutations.
Chang TC; Wu SL; Hsiao YL
Acta Cytol; 2005; 49(5):477-82. PubMed ID: 16334022
[TBL] [Abstract][Full Text] [Related]
29. Thyroid carcinomas involving follicular and parafollicular C cells: seventeen cases with characterization of RET oncogenic activation.
Vantyghem MC; Pigny P; Leteurtre E; Leclerc L; Bauters C; Douillard C; D'Herbomez M; Carnaille B; Proye C; Wemeau JL; Lecomte-Houcke M
Thyroid; 2004 Oct; 14(10):842-7. PubMed ID: 15588381
[TBL] [Abstract][Full Text] [Related]
30. Molecular pathology of hereditary and sporadic medullary thyroid carcinomas.
Chernock RD; Hagemann IS
Am J Clin Pathol; 2015 Jun; 143(6):768-77. PubMed ID: 25972318
[TBL] [Abstract][Full Text] [Related]
31. Leukemia inhibitory factor can mediate Ras/Raf/MEK/ERK-induced growth inhibitory signaling in medullary thyroid cancer cells.
Arthan D; Hong SK; Park JI
Cancer Lett; 2010 Nov; 297(1):31-41. PubMed ID: 20570039
[TBL] [Abstract][Full Text] [Related]
32. A comprehensive overview of the role of the RET proto-oncogene in thyroid carcinoma.
Romei C; Ciampi R; Elisei R
Nat Rev Endocrinol; 2016 Apr; 12(4):192-202. PubMed ID: 26868437
[TBL] [Abstract][Full Text] [Related]
33. High-throughput mutation profiling improves diagnostic stratification of sporadic medullary thyroid carcinomas.
Simbolo M; Mian C; Barollo S; Fassan M; Mafficini A; Neves D; Scardoni M; Pennelli G; Rugge M; Pelizzo MR; Cavedon E; Fugazzola L; Scarpa A
Virchows Arch; 2014 Jul; 465(1):73-8. PubMed ID: 24828033
[TBL] [Abstract][Full Text] [Related]
34. Management of medullary thyroid carcinoma.
Jiménez C; Hu MI; Gagel RF
Endocrinol Metab Clin North Am; 2008 Jun; 37(2):481-96, x-xi. PubMed ID: 18502338
[TBL] [Abstract][Full Text] [Related]
35. Change in the spectrum of RET mutations diagnosed between 1994 and 2006.
Frank-Raue K; Rondot S; Schulze E; Raue F
Clin Lab; 2007; 53(5-6):273-82. PubMed ID: 17605401
[TBL] [Abstract][Full Text] [Related]
36. Mutation of the RET proto-oncogene is correlated with RET immunostaining in subpopulations of cells in sporadic medullary thyroid carcinoma.
Eng C; Thomas GA; Neuberg DS; Mulligan LM; Healey CS; Houghton C; Frilling A; Raue F; Williams ED; Ponder BA
J Clin Endocrinol Metab; 1998 Dec; 83(12):4310-3. PubMed ID: 9851769
[TBL] [Abstract][Full Text] [Related]
37. Medullary thyroid carcinoma.
Pacini F; Castagna MG; Cipri C; Schlumberger M
Clin Oncol (R Coll Radiol); 2010 Aug; 22(6):475-85. PubMed ID: 20627492
[TBL] [Abstract][Full Text] [Related]
38. High prevalence of exon 8 G533C mutation in apparently sporadic medullary thyroid carcinoma in Greece.
Sarika HL; Papathoma A; Garofalaki M; Vasileiou V; Vlassopoulou B; Anastasiou E; Alevizaki M
Clin Endocrinol (Oxf); 2012 Dec; 77(6):857-62. PubMed ID: 22676047
[TBL] [Abstract][Full Text] [Related]
39. Germline RET mutations in exons 10 and 11: an Iranian survey of 57 medullary thyroid carcinoma cases.
Hedayati M; Nabipour I; Rezaei-Ghaleh N; Azizi F
Med J Malaysia; 2006 Dec; 61(5):564-9. PubMed ID: 17623957
[TBL] [Abstract][Full Text] [Related]
40. [The treatment of medullary thyroid cancer].
Fujita T; Fujimori M
Gan To Kagaku Ryoho; 2009 Oct; 36(10):1627-31. PubMed ID: 19838021
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]